These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 27370399)

  • 1. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.
    Dermawan JK; Hitomi M; Silver DJ; Wu Q; Sandlesh P; Sloan AE; Purmal AA; Gurova KV; Rich JN; Lathia JD; Stark GR; Venere M
    Cancer Res; 2016 Apr; 76(8):2432-42. PubMed ID: 26921329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
    Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
    Banelli B; Daga A; Forlani A; Allemanni G; Marubbi D; Pistillo MP; Profumo A; Romani M
    Oncotarget; 2017 May; 8(21):34896-34910. PubMed ID: 28432280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
    Guo G; Gong K; Puliyappadamba VT; Panchani N; Pan E; Mukherjee B; Damanwalla Z; Bharia S; Hatanpaa KJ; Gerber DE; Mickey BE; Patel TR; Sarkaria JN; Zhao D; Burma S; Habib AA
    Neuro Oncol; 2019 Dec; 21(12):1529-1539. PubMed ID: 31363754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
    Nadkarni A; Shrivastav M; Mladek AC; Schwingler PM; Grogan PT; Chen J; Sarkaria JN
    J Neurooncol; 2012 Dec; 110(3):349-57. PubMed ID: 23054561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
    Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
    Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
    Triscott J; Lee C; Hu K; Fotovati A; Berns R; Pambid M; Luk M; Kast RE; Kong E; Toyota E; Yip S; Toyota B; Dunn SE
    Oncotarget; 2012 Oct; 3(10):1112-23. PubMed ID: 23047041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
    Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
    Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.